Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSURF-IPF: Inhaled Alveofact in Idiopathic Pulmonary Fibrosis
2023-508544-22-00Phase 2Authorised
- Sponsor
- Philipps-Universität Marburg
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of calfactant in idiopathic pulmonary fibrosis (IPF), sponsored by Philipps-Universität Marburg. Primary endpoint: Mean intra-individual difference in percentage change in FVC. Planned start Jul 2024; status: authorised.
02
Drugs
calfactant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-508544-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508544-22-00.